Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research

Vikas Gupta*, Adriana K. Malone, Parameswaran N. Hari, Kwang Woo Ahn, Zhen-Huan Hu, Robert Peter Gale, Karen K. Ballen, Mehdi Hamadani, Eduardo Olavarria, Aaron T. Gerds, Edmund K. Waller, Luciano J. Costa, Joseph H. Antin, Rammurti T. Kamble, Koen M. van Besien, Bipin N. Savani, Harry C. Schouten, Jeffrey Szer, Jean-Yves Cahn, Marcos J. de LimaBaldeep Wirk, Mahmoud D. Aljurf, Uday Popat, Nelli Bejanyan, Mark R. Litzow, Maxim Norkin, Ian D. Lewis, Gregory A. Hale, Ann E. Woolfrey, Alan M. Miller, Celalettin Ustun, Madan H. Jagasia, Michael Lill, Richard T. Maziarz, Jorge Cortes, Matt E. Kalaycio, Wael Saber

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


We evaluated outcomes and associated prognostic factors in 233 patients undergoing allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis (MF) using reduced-intensity conditioning (RIC). The median age at RIC HCT was 55 yr. Donors were a matched sibling donor (MSD) in 34% of RIC HO's, an HLA well-matched unrelated donor CURD) in 45%, and a partially matched/mismatched URD in 21%. Risk stratification according to the Dynamic International Prognostic Scoring System (DIPSS) was 12% low, 49% intermediate-1, 37% intermediate-2, and 1% high. The probability of survival at 5 yr was 47% (95% confidence interval [CI], 40% to 53%). In a multivariate analysis, donor type was the sole independent factor associated with survival. Adjusted probabilities of survival at 5-yr were 56% (95% CI, 44% to 67%) for MSD, 48% (95% CI, 37% to 58%) for well-matched URD, and 34% (95% CI, 21% to 47%) for partially matched/mismatched URD (P =.002). The relative risk (RR) for NRM was 3.92 (P =.006) for well-matched URD and 9.37 (P
Original languageEnglish
Pages (from-to)89-97
JournalBiology of Blood and Marrow Transplantation
Issue number1
Publication statusPublished - Jan 2014


  • Myelofibrosis
  • Allogeneic transplantation
  • Reduced intensity
  • Prognosis

Cite this